Tarsus Pharmaceuticals (TARS) Income from Continuing Operations (2019 - 2026)
Tarsus Pharmaceuticals' (TARS) quarterly Income from Continuing Operations came in at 6928000.0 in Q1 2026, up 72.33% year-on-year from 4020166.67 in Q1 2025, and down 11.03% quarter-over-quarter from 6240000.0 in Q4 2025.
Tarsus Pharmaceuticals (TARS) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Tarsus Pharmaceuticals' Income from Continuing Operations history runs 8 years deep, the most recent figure standing at 6928000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 72.33% year-over-year to 6928000.0 in Q1 2026; TTM through Mar 2026 was 149541000.0, a 45.27% decrease from a year earlier, with the FY2025 full-year figure at 66418000.0, up 42.52% from the prior year.
- Income from Continuing Operations fell to 6928000.0 in Q1 2026 per TARS's latest filing, from 6240000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 5471000.0 in Q2 2022 and bottomed at 123690000.0 in Q2 2025.
- The 5-year median for Income from Continuing Operations is 23343000.0 (2023), against an average of 28534352.94.
- Across the five-year window, Income from Continuing Operations slumped 474.12% in 2023 and surged 73.03% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 13102000.0 in 2022, then plunged by 224.08% to 42461000.0 in 2023, then jumped by 45.51% to 23135000.0 in 2024, then jumped by 73.03% to 6240000.0 in 2025, then retreated by 11.03% to 6928000.0 in 2026.
- Per Business Quant, the three latest TARS Income from Continuing Operations figures stand at 6928000.0 (Q1 2026), 6240000.0 (Q4 2025), and 12683000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Tarsus Pharmaceuticals | 2.52 Bn | 2.41 Bn | 152.66 Mn | -6.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.93 Mn |
| Dec 31, 2025 | -6.24 Mn |
| Sep 30, 2025 | -12.68 Mn |
| Jun 30, 2025 | -123.69 Mn |
| Mar 31, 2025 | -25.04 Mn |
| Dec 31, 2024 | -23.14 Mn |
| Sep 30, 2024 | -23.49 Mn |
| Jun 30, 2024 | -31.28 Mn |
| Mar 31, 2024 | -35.55 Mn |
| Dec 31, 2023 | -42.46 Mn |
| Sep 30, 2023 | -38.95 Mn |
| Jun 30, 2023 | -31.41 Mn |
| Mar 31, 2023 | -23.34 Mn |
| Dec 31, 2022 | -13.10 Mn |
| Sep 30, 2022 | -22.47 Mn |
| Jun 30, 2022 | -5.47 Mn |
| Mar 31, 2022 | -19.84 Mn |
| Dec 31, 2021 | -14.50 Mn |
| Sep 30, 2021 | -15.36 Mn |
| Jun 30, 2021 | 7.17 Mn |